Preoperatiye interleukin-2 immunotherapy in pancreatic cancer: Preliminary results

Carlo Angelini, Giorgio Bovo, Pietro Muselli, Chiara Mussi, Stefano Crippa, Roberto Caprotti, Franco Uggeri

Research output: Contribution to journalArticle

Abstract

Background/Aims: Cancer patients' immunodeficiency, made worse by surgery, represents a poor prognostic factor for postoperative complications and long-term survival. Interleukin-2 has been shown to contrast the immunodeficiency related to the tumor and surgical treatment. The aim of this study is to evaluate the effectiveness of preoperative immunotherapy with interleukin-2 in pancreatic cancer patients. Methodology: 19 patients with pancreatic cancer undergoing radical surgery were divided in 2 different groups. Group 1: 9 patients treated with preoperative Interleukin-2 (9 million IU of IL-2 s.c. for 3 consecutive days) followed by pancreaticoduodenectomy after 36 hours; group 2:10 patients who underwent pancreaticoduodenectomy without any neoadjuvant treatment. Two groups were well matched for age, sex, stage of disease, preoperative tumor markers and preoperative hematological assessment. Inflammatory cells' infiltration on the resected specimens, pre- and postoperative blood lymphocyte counts were evaluated as well as postoperative complications and survival and compared between the groups. Results: Hematological and histological findings showed no significant difference between the 2 groups. Postoperative complications were more frequent in the control than in the treated group (p

Original languageEnglish
Pages (from-to)141-144
Number of pages4
JournalHepato-Gastroenterology
Volume53
Issue number67
Publication statusPublished - Jan 2006

Fingerprint

Pancreatic Neoplasms
Immunotherapy
Interleukin-2
Pancreaticoduodenectomy
Interleukin-9
Neoadjuvant Therapy
Survival
Lymphocyte Count
Tumor Biomarkers
Neoplasms
Therapeutics

Keywords

  • Cancer
  • Immunodeficiency
  • Immunotherapy
  • Interleukin-2
  • Lymphocytopenia
  • Pancreatic cancer

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Angelini, C., Bovo, G., Muselli, P., Mussi, C., Crippa, S., Caprotti, R., & Uggeri, F. (2006). Preoperatiye interleukin-2 immunotherapy in pancreatic cancer: Preliminary results. Hepato-Gastroenterology, 53(67), 141-144.

Preoperatiye interleukin-2 immunotherapy in pancreatic cancer : Preliminary results. / Angelini, Carlo; Bovo, Giorgio; Muselli, Pietro; Mussi, Chiara; Crippa, Stefano; Caprotti, Roberto; Uggeri, Franco.

In: Hepato-Gastroenterology, Vol. 53, No. 67, 01.2006, p. 141-144.

Research output: Contribution to journalArticle

Angelini, C, Bovo, G, Muselli, P, Mussi, C, Crippa, S, Caprotti, R & Uggeri, F 2006, 'Preoperatiye interleukin-2 immunotherapy in pancreatic cancer: Preliminary results', Hepato-Gastroenterology, vol. 53, no. 67, pp. 141-144.
Angelini C, Bovo G, Muselli P, Mussi C, Crippa S, Caprotti R et al. Preoperatiye interleukin-2 immunotherapy in pancreatic cancer: Preliminary results. Hepato-Gastroenterology. 2006 Jan;53(67):141-144.
Angelini, Carlo ; Bovo, Giorgio ; Muselli, Pietro ; Mussi, Chiara ; Crippa, Stefano ; Caprotti, Roberto ; Uggeri, Franco. / Preoperatiye interleukin-2 immunotherapy in pancreatic cancer : Preliminary results. In: Hepato-Gastroenterology. 2006 ; Vol. 53, No. 67. pp. 141-144.
@article{1b8a77cb8daa468ea1f1eadd4a91bad6,
title = "Preoperatiye interleukin-2 immunotherapy in pancreatic cancer: Preliminary results",
abstract = "Background/Aims: Cancer patients' immunodeficiency, made worse by surgery, represents a poor prognostic factor for postoperative complications and long-term survival. Interleukin-2 has been shown to contrast the immunodeficiency related to the tumor and surgical treatment. The aim of this study is to evaluate the effectiveness of preoperative immunotherapy with interleukin-2 in pancreatic cancer patients. Methodology: 19 patients with pancreatic cancer undergoing radical surgery were divided in 2 different groups. Group 1: 9 patients treated with preoperative Interleukin-2 (9 million IU of IL-2 s.c. for 3 consecutive days) followed by pancreaticoduodenectomy after 36 hours; group 2:10 patients who underwent pancreaticoduodenectomy without any neoadjuvant treatment. Two groups were well matched for age, sex, stage of disease, preoperative tumor markers and preoperative hematological assessment. Inflammatory cells' infiltration on the resected specimens, pre- and postoperative blood lymphocyte counts were evaluated as well as postoperative complications and survival and compared between the groups. Results: Hematological and histological findings showed no significant difference between the 2 groups. Postoperative complications were more frequent in the control than in the treated group (p",
keywords = "Cancer, Immunodeficiency, Immunotherapy, Interleukin-2, Lymphocytopenia, Pancreatic cancer",
author = "Carlo Angelini and Giorgio Bovo and Pietro Muselli and Chiara Mussi and Stefano Crippa and Roberto Caprotti and Franco Uggeri",
year = "2006",
month = "1",
language = "English",
volume = "53",
pages = "141--144",
journal = "Acta hepato-splenologica",
issn = "0172-6390",
publisher = "H.G.E. Update Medical Publishing Ltd.",
number = "67",

}

TY - JOUR

T1 - Preoperatiye interleukin-2 immunotherapy in pancreatic cancer

T2 - Preliminary results

AU - Angelini, Carlo

AU - Bovo, Giorgio

AU - Muselli, Pietro

AU - Mussi, Chiara

AU - Crippa, Stefano

AU - Caprotti, Roberto

AU - Uggeri, Franco

PY - 2006/1

Y1 - 2006/1

N2 - Background/Aims: Cancer patients' immunodeficiency, made worse by surgery, represents a poor prognostic factor for postoperative complications and long-term survival. Interleukin-2 has been shown to contrast the immunodeficiency related to the tumor and surgical treatment. The aim of this study is to evaluate the effectiveness of preoperative immunotherapy with interleukin-2 in pancreatic cancer patients. Methodology: 19 patients with pancreatic cancer undergoing radical surgery were divided in 2 different groups. Group 1: 9 patients treated with preoperative Interleukin-2 (9 million IU of IL-2 s.c. for 3 consecutive days) followed by pancreaticoduodenectomy after 36 hours; group 2:10 patients who underwent pancreaticoduodenectomy without any neoadjuvant treatment. Two groups were well matched for age, sex, stage of disease, preoperative tumor markers and preoperative hematological assessment. Inflammatory cells' infiltration on the resected specimens, pre- and postoperative blood lymphocyte counts were evaluated as well as postoperative complications and survival and compared between the groups. Results: Hematological and histological findings showed no significant difference between the 2 groups. Postoperative complications were more frequent in the control than in the treated group (p

AB - Background/Aims: Cancer patients' immunodeficiency, made worse by surgery, represents a poor prognostic factor for postoperative complications and long-term survival. Interleukin-2 has been shown to contrast the immunodeficiency related to the tumor and surgical treatment. The aim of this study is to evaluate the effectiveness of preoperative immunotherapy with interleukin-2 in pancreatic cancer patients. Methodology: 19 patients with pancreatic cancer undergoing radical surgery were divided in 2 different groups. Group 1: 9 patients treated with preoperative Interleukin-2 (9 million IU of IL-2 s.c. for 3 consecutive days) followed by pancreaticoduodenectomy after 36 hours; group 2:10 patients who underwent pancreaticoduodenectomy without any neoadjuvant treatment. Two groups were well matched for age, sex, stage of disease, preoperative tumor markers and preoperative hematological assessment. Inflammatory cells' infiltration on the resected specimens, pre- and postoperative blood lymphocyte counts were evaluated as well as postoperative complications and survival and compared between the groups. Results: Hematological and histological findings showed no significant difference between the 2 groups. Postoperative complications were more frequent in the control than in the treated group (p

KW - Cancer

KW - Immunodeficiency

KW - Immunotherapy

KW - Interleukin-2

KW - Lymphocytopenia

KW - Pancreatic cancer

UR - http://www.scopus.com/inward/record.url?scp=33344475248&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33344475248&partnerID=8YFLogxK

M3 - Article

C2 - 16506394

AN - SCOPUS:33344475248

VL - 53

SP - 141

EP - 144

JO - Acta hepato-splenologica

JF - Acta hepato-splenologica

SN - 0172-6390

IS - 67

ER -